Evotec (NASDAQ:EVO) Sees Strong Trading Volume – Here’s What Happened

Evotec SE (NASDAQ:EVO) shares saw unusually-strong trading volume on Wednesday . Approximately 45,074 shares were traded during trading, a decline of 16% from the previous session’s volume of 53,452 shares.The stock last traded at $3.91 and had previously closed at $3.92.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Evotec in a research report on Thursday, November 7th.

Evotec Stock Performance

The firm has a 50 day simple moving average of $4.32 and a 200-day simple moving average of $4.09. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EVO. Wellington Management Group LLP lifted its holdings in Evotec by 29.7% during the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after purchasing an additional 602,858 shares during the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of Evotec in the fourth quarter valued at about $166,000. DCF Advisers LLC lifted its stake in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock worth $956,000 after buying an additional 12,816 shares during the last quarter. CSS LLC IL bought a new stake in shares of Evotec during the 4th quarter worth about $50,000. Finally, Bank of America Corp DE grew its stake in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the last quarter. 5.81% of the stock is owned by institutional investors and hedge funds.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.